Elevated intracellular cAMP concentration mediates growth suppression in glioma cells

Biochem Pharmacol. 2020 Apr:174:113823. doi: 10.1016/j.bcp.2020.113823. Epub 2020 Jan 25.

Abstract

Supressed levels of intracellular cAMP have been associated with malignancy. Thus, elevating cAMP through activation of adenylyl cyclase (AC) or by inhibition of phosphodiesterase (PDE) may be therapeutically beneficial. Here, we demonstrate that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors with differing selectivity profiles. Forskolin suppressed cell growth in a PKA-dependent manner by inducing a G2/M phase cell cycle arrest. In contrast, trequinsin (a non-selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but also stimulated (independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. Interestingly, a cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a manner analogous to forskolin but not trequinsin. Finally, we demonstrate that concomitant targeting of both AC and PDEs synergistically elevated intracellular cAMP levels thereby potentiating their antiproliferative actions.

Keywords: Caspase; Cell cycle; Glioma; Phosphodiesterase inhibitors; Proliferation; cAMP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Proliferation / physiology*
  • Colforsin / pharmacology
  • Cyclic AMP / metabolism*
  • Glioma / metabolism*
  • Glioma / pathology
  • Growth Inhibitors / pharmacology*
  • Humans
  • Intracellular Fluid / drug effects
  • Intracellular Fluid / metabolism*
  • Phosphodiesterase Inhibitors / pharmacology
  • Rats

Substances

  • Growth Inhibitors
  • Phosphodiesterase Inhibitors
  • Colforsin
  • Cyclic AMP
  • Adenylyl Cyclases